## **AMENDMENTS TO THE CLAIMS**

1. (original) A heteroaryl derivative of the formula (1):

$$R^{1}-W^{1}-O-W^{2}-Ar^{1}-W^{3}-Z$$
  $W^{4}-Ar^{2}$  (1)

(wherein Ring Z is an optionally substituted heteroaryl;

R<sup>1</sup> is a carboxyl group, an alkoxycarbonyl group, an optionally substituted carbamoyl group, an optionally substituted cyclic aminocarbonyl group, an optionally substituted alkylsulfonylcarbamoyl group, an optionally substituted arylsulfonylcarbamoyl group, or a tetrazolyl group;

W<sup>1</sup> and W<sup>2</sup> are an optionally substituted lower alkylene;

Ar<sup>1</sup> is an optionally substituted arylene or an optionally substituted heteroarylene;

 $W^3$  is a single bond, a lower alkylene, a lower alkenylene, or  $-Y^1-W^5$ - (in which  $Y^1$  is an oxygen atom, a sulfur atom, -S(O)- or  $-S(O)_2$ -, and  $W^5$  is a lower alkylene or a lower alkenylene);

 $W^4$  is a single bond,  $-NR^{10}$ -,  $-NR^{10}$ - $W^6$ - (in which  $R^{10}$  is a hydrogen atom, or an optionally substituted lower alkyl, and  $W^6$  is a lower alkylene), a lower alkylene, or a lower alkenylene;

Ar<sup>2</sup> is an optionally substituted aryl or an optionally substituted heteroaryl), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Application No.: NEW Docket No.: 0020-5458PUS1

2. (original) The heteroaryl derivative according to claim 1, wherein  $W^3$  is a lower alkylene, a lower alkenylene, or  $-Y^1-W^5$ - (in which  $Y^1$  is an oxygen atom, a sulfur atom, -S(O)- or  $-S(O)_2$ -, and  $W^5$  is a lower alkylene or a lower alkenylene), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

- 3. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is an optionally substituted pyrrole ring, an optionally substituted pyrazole ring, an optionally substituted imidazole ring, an optionally substituted indole ring, an optionally substituted indazole ring, or an optionally substituted benzimidazole ring, W<sup>3</sup> is a C<sub>1</sub>-C<sub>5</sub> alkylene, a C<sub>2</sub>-C<sub>5</sub> alkenylene, or -Y<sup>1</sup>'-W<sup>5</sup>'- (in which Y<sup>1</sup>' is an oxygen atom or a sulfur atom, and W<sup>5</sup>' is a C<sub>1</sub>-C<sub>5</sub> alkylene or a C<sub>2</sub>-C<sub>5</sub> alkenylene), W<sup>4</sup> is a single bond, -NR<sup>10</sup>-, a C<sub>1</sub>-C<sub>4</sub> alkylene, or a C<sub>2</sub>-C<sub>4</sub> alkenylene, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- 4. (original) The heteroaryl compound according to claim 1, wherein Ring Z is selected from the following formulae (2):

(in which the number of R<sup>2</sup> may be one or more, and each is independently selected from a hydrogen atom, a halogen atom, an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted thiol, the number of R<sup>3</sup> may be one or more, and each is independently selected from a hydrogen atom, a halogen atom, an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted thiol, an optionally substituted hydroxy, an optionally substituted non-aromatic heterocyclic group, an optionally substituted amino, an optionally substituted acyl, and an alkylsulfonyl, and either of the binding direction of these groups may be acceptable), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Application No.: NEW Docket No.: 0020-5458PUS1

5. (original) The heteroaryl compound according to claim 1 or claim 2, wherein Ring Z is an optionally substituted pyrrole ring, an optionally substituted imidazole ring, or an optionally substituted benzimidazole ring, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

- 6. (original) The heteroaryl compound according to any one of claims 1 to 3, wherein  $W^1$  and  $W^2$  are an optionally substituted straight chain  $C_1$ - $C_3$  alkylene group, or an optionally substituted  $C_3$ - $C_6$  alkylene group containing a cyclic structure, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- 7. (original) The heteroaryl compound according to any one of claims 1 to 3, wherein  $W^1$  and  $W^2$  are an optionally substituted methylene or ethylene,  $W^3$  is a straight chain  $C_2$ - $C_4$  alkylene or  $C_3$ - $C_4$  alkenylene, or  $-Y^1$ "- $W^5$ "- (in which  $Y^1$ " is an oxygen atom and  $W^5$ " is a straight chain  $C_2$ - $C_4$  alkylene),  $W^4$  is a single bond,  $-NR^{10}$ -, methylene, or transvinylene, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- 8. (currently amended) The heteroaryl compound according to any one of claims 1 to 6 claim 1, wherein Ar<sup>1</sup> is an optionally substituted phenylene, and the binding position of W<sup>2</sup> is at meta-position or para-position with respect to the binding position of W<sup>3</sup>, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

9. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is a group of the formula (3):

(in which the number of  $R^2$ , may be one or more, and each is independently selected from a hydrogen atom, methyl, an optionally substituted phenyl, and an optionally substituted heteroaryl),  $R^1$  is a carboxyl group, an optionally substituted alkylsulfonylcarbamoyl group, or a tetrazolyl group,  $W^1$  and  $W^2$  are an optionally substituted methylene or ethylene,  $Ar^1$  is an optionally substituted phenylene,  $W^3$  is a straight chain  $C_2$ - $C_4$  alkylene or  $C_3$ - $C_4$  alkenylene,  $Ar^2$  is an optionally substituted phenyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

10. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is a group of the formula (4):

(in which the number of  $R^2$ ' may be one or more, and each is independently selected from a hydrogen atom, methyl, an optionally substituted phenyl, and an optionally substituted heteroaryl),  $R^1$  is a carboxyl group, an optionally substituted alkylsulfonylcarbamoyl group, or a tetrazolyl group,  $W^1$  and  $W^2$  are an optionally substituted methylene or ethylene,  $Ar^1$  is an optionally substituted phenylene,  $W^3$  is a straight chain  $C_2$ - $C_4$  alkylene or  $C_3$ - $C_4$  alkenylene,  $Ar^2$ 

6 DRN/sII

is an optionally substituted phenyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

11. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is selected from the following formulae (5):

R<sup>1</sup> is a carboxyl group, W<sup>1</sup> is an optionally substituted methylene or ethylene, W<sup>2</sup> is methylene, Ar<sup>1</sup> is phenylene, W<sup>3</sup> is propenylene or propylene, Ar<sup>2</sup> is an optionally substituted phenyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

12. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is selected from the following formulae (6):

$$\mathbb{R}^{2^{\prime}}$$
  $\mathbb{R}^{2^{\prime}}$  (6)

(in which the number of R<sup>2</sup>, may be one or more, and each is independently selected from a hydrogen atom, methyl, an optionally substituted phenyl, and an optionally substituted heteroaryl), R<sup>1</sup> is a carboxyl group, W<sup>1</sup> is an optionally substituted methylene, or ethylene, W<sup>2</sup> is

methylene, Ar<sup>1</sup> is phenylene, W<sup>3</sup> is propenylene or propylene, Ar<sup>2</sup> is an optionally substituted phenyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

13. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is a group of the formula (7):

R<sup>1</sup> is a carboxyl group, W<sup>1</sup> is an optionally substituted methylene, W<sup>2</sup> is methylene, Ar<sup>1</sup> is phenylene, W<sup>3</sup> is propenylene or propylene, Ar<sup>2</sup> is an optionally substituted phenyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

14. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is a group of the formula (7):

R<sup>1</sup> is a carboxyl group, W<sup>1</sup> is a methylene optionally substituted by an alkyl having 1 to 3 carbon atoms, W<sup>2</sup> is methylene, Ar<sup>1</sup> is phenylene, W<sup>3</sup> is propenylene or propylene, Ar<sup>2</sup> is a phenyl optionally substituted by an alkyl having 1 to 3 carbon atoms or an alkoxy having 1 to 3 carbon atoms, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

15. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is selected from the following formulae (8):

R<sup>1</sup> is a carboxyl group, W<sup>1</sup> is a methylene optionally substituted by an alkyl group having 1 to 3 carbon atoms, W<sup>2</sup> is methylene, Ar<sup>1</sup> is phenylene, W<sup>3</sup> is propenylene or propylene, Ar<sup>2</sup> is a phenyl optionally substituted by an alkyl having 1 to 3 carbon atoms or an alkoxy having 1 to 3 carbon atoms, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

16. (original) The heteroaryl derivative according to claim 1, wherein Ring Z is a group of the formula (9):

R<sup>1</sup> is a carboxyl group, W<sup>1</sup> is a methylene optionally substituted by an alkyl group having 1 to 3 carbon atoms, W<sup>2</sup> is methylene, Ar<sup>1</sup> is phenylene, W<sup>3</sup> is propenylene, Ar<sup>2</sup> is a phenyl optionally substituted by an alkyl group having 1 to 3 carbon atoms or an alkoxy group having 1 to 3 carbon atoms, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

17. (original) The heteroaryl derivative according to claim 1, which is a compound selected from the following formulae (10):

HO2C 
$$\rightarrow$$
 HO2C  $\rightarrow$  HO

or a prodrug thereof, or a pharmaceutically acceptable salt thereof.